Is Now a Good Moment to Include Labcorp Shares in Your Investment Portfolio?

Labcorp Holdings Inc.: Growth Prospects and Challenges Ahead

Labcorp Holdings Inc. (LH) is positioned for continued expansion in the near future, driven by its focus on growing its testing portfolio in high-potential fields such as neurology and autoimmune disorders. The company’s commitment to strengthening collaborations with hospitals and healthcare systems has solidified its presence in key markets. Additionally, the ongoing benefits from its LaunchPad initiative are contributing to improved profit margins. However, Labcorp faces obstacles from unfavorable currency movements and broader economic uncertainties that could impact its performance.

Over the past year, Labcorp’s stock has climbed 10.2%, outpacing the medical products industry’s 6.4% gain but trailing the S&P 500’s 21.8% rise.

With a market value of $23.61 billion, Labcorp stands out in the healthcare diagnostics sector. Its earnings yield of 6.2% surpasses the industry average of 4.1%. Over the last four quarters, the company has exceeded earnings expectations by an average of 3.07%.

Key Drivers of Labcorp’s Growth

Expanding in High-Growth Specialties

Labcorp is broadening its reach in specialized testing areas such as oncology, women’s health, autoimmune diseases, and neurology—fields projected to grow significantly faster than other therapeutic segments. In oncology alone, Labcorp now provides over 450 tests covering a wide range of cancer types and stages, showcasing its advanced diagnostic capabilities. The acquisition of Invitae has further extended its genetic testing services. Notably, Labcorp’s PGDx elio tissue complete has received CE marking under the EU’s new In Vitro Diagnostic Regulation, making it the first test in the region authorized for comprehensive solid tumor profiling.

The company has also enhanced its neurology offerings by introducing two new Alzheimer’s tests for both specialty and primary care. Labcorp is partnering with Geneoscopy to increase access to the FDA-approved ColoSense at-home colorectal cancer screening test.

Image Source: Zacks Investment Research

Strategic Acquisitions and Partnerships

Labcorp has consistently expanded its network through strategic alliances with health systems and regional laboratories, thereby increasing its reach among patients and providers. In 2025, the company acquired select oncology and clinical testing assets from BioReference Health and took over North Mississippi Health Services’ ambulatory outreach laboratory business, becoming the referral lab for its seven hospitals and clinics.

During the fourth quarter, Labcorp invested $258 million in acquisitions, which contributed 1.2% to its revenue growth. Recent deals include acquiring outreach assets from Community Health Systems, anatomic pathology assets from Incyte Diagnostics, and outreach laboratory services from Parkview Health.

Operational Improvements and Digital Innovation

Labcorp’s LaunchPad business process improvement program delivered annual savings of $100–$125 million in 2025. The company has also introduced AI-driven tools like the Labcorp Test Finder, which streamlines appointment scheduling and results delivery for patients. This tool is now integrated into the Labcorp Diagnostic Assistant, accessible via electronic health records and the Labcorp Link platform.

Additionally, Labcorp rolled out eClaim Assist, a digital solution that simplifies patient claim updates and responses, reducing processing time and boosting efficiency. For the full year 2025, Labcorp improved its enterprise margin by over 50 basis points, thanks to robust revenue growth, disciplined cost control, and LaunchPad synergies.

Challenges Facing Labcorp

Currency Fluctuations

Labcorp’s significant international operations expose it to risks from currency volatility. The recent strengthening of the U.S. dollar, which analysts expect to continue, could negatively impact the company’s overseas revenue.

Macroeconomic Pressures

The company’s business depends heavily on demand for diagnostic testing and drug development services from a variety of clients, including patients, healthcare providers, and medical device companies. Recent global economic instability, particularly inflation, has dampened demand and affected customers’ ability to pay, thereby squeezing Labcorp’s profitability. Ongoing geopolitical tensions and retaliatory tariffs are also straining supply chains and driving up costs.

Labcorp Stock Outlook

In the last month, analysts have slightly raised their 2026 earnings per share forecast for Labcorp by 0.3% to $17.65. Revenue projections for 2026 stand at $14.67 billion, representing a 5.2% increase over 2025 estimates.

Leading MedTech Stocks to Watch

• Phibro Animal Health (PAHC): With an earnings yield of 5.5%, well above the industry’s 2.5%, Phibro has beaten earnings expectations in each of the past four quarters, averaging a 20.2% surprise. Its shares have soared 117.5% over the past year, while the industry declined by 15.1%. PAHC currently holds a Zacks Rank #1 (Strong Buy).
• Envista (NVST): Also rated Zacks Rank #1, Envista boasts a 4.8% earnings yield compared to the industry’s 2.5%. The company’s stock has jumped 54% in the past year, and it has exceeded earnings estimates in each of the last four quarters, with an average surprise of 16.4%.
• Align Technology (ALGN): Currently holding a Zacks Rank #2 (Buy), Align Technology is projected to achieve a long-term earnings growth rate of 10.1%, outpacing the industry’s 9.1%. Its shares have gained 7.5% over the past year, while the industry grew by 22%. The company beat earnings estimates in three of the last four quarters, with an average surprise of 6.2%.

Unlocking the Next Wave of AI Investment

The upcoming phase of AI innovation is expected to generate substantial wealth for early investors, with the potential to add trillions to the global economy and transform nearly every industry.

Those who invested in companies like Nvidia at the right moment have already seen remarkable returns. However, the rapid gains from the initial surge in AI stocks may soon plateau, paving the way for a new group of emerging leaders in the sector.

Zacks’ report, AI Boom 2.0: The Second Wave, highlights four lesser-known companies that could become the next big names in AI.

Additional Resources